WO2014071426A1 - Alun pour le traitement de maladies cutanées - Google Patents

Alun pour le traitement de maladies cutanées Download PDF

Info

Publication number
WO2014071426A1
WO2014071426A1 PCT/AT2013/000182 AT2013000182W WO2014071426A1 WO 2014071426 A1 WO2014071426 A1 WO 2014071426A1 AT 2013000182 W AT2013000182 W AT 2013000182W WO 2014071426 A1 WO2014071426 A1 WO 2014071426A1
Authority
WO
WIPO (PCT)
Prior art keywords
alum
skin
preparation according
preparation
ammonium alum
Prior art date
Application number
PCT/AT2013/000182
Other languages
German (de)
English (en)
Inventor
Erna SPIRK
Markus LIST
Original Assignee
Gl & Partners Og
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gl & Partners Og filed Critical Gl & Partners Og
Priority to DE212013000223.8U priority Critical patent/DE212013000223U1/de
Publication of WO2014071426A1 publication Critical patent/WO2014071426A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Definitions

  • the invention relates to the treatment and / or alleviation of skin diseases, in particular eczema, such as eczema. Eczema, and psoriasis.
  • Skin diseases can have many different causes. For example, many people have a hereditary predisposition to psoriasis or atopic eczema (atopic dermatitis). The occurrence of such diseases can, for. B. be amplified by stress or another infection. In addition, the course of the disease can worsen again by a bacterial or viral infection. With many skin diseases one still does not know about the exact mechanism of origin, whereby in many cases regulation disturbances of the immune system are considered cause.
  • Easier skin diseases can be treated with anti-inflammatory ointments or creams.
  • Some of these ointments contain disinfectants or cortisone and because of their side effects can only be used at short notice.
  • the advantage is that the active ingredient works only locally. More serious skin diseases often do not respond to a sole local therapy with ointments or creams.
  • systemic drugs eg in tablet form, are used, which can have side effects.
  • infectious diseases of the skin by bacteria or viruses require the administration of antibiotics or similar agents.
  • a particular problem is the occurrence of atopic Ekze ⁇ men (neurodermatitis), in which there is a chronic, non-infectious skin disease.
  • Atopic dermatitis is considered incurable but treatable.
  • the therapy consists mainly of treatment of characteristic skin dryness and external use of. anti-inflammatory agents. However, such drugs usually have side effects, so that an application over a longer period is not recommended.
  • Psoriasis is also relatively widespread. It is a skin disease characterized by severe scaly, punctate to palm-sized skin areas (often on the knees, elbows and scalp) as well as changes to the nails.
  • Various approaches have been known for the treatment of psoriasis, which consist in the external application of various substances, but do not cure, but only cause relief of symptoms.
  • the external effect is associated with numerous disadvantages.
  • many liquid preparations contain alcohol to dissolve the active ingredients, which can further worsen an existing dry skin condition.
  • creams contain emulsifiers to bind the lipophilic to the aqueous phase, but are not always well tolerated by sensitive skin.
  • Gels have a high water content or alcohol content, which can dissolve the cement substances from the uppermost skin layer and additionally dry out the skin.
  • the invention is therefore based on the object to enable an improvement in the treatment and / or alleviation of skin diseases, in particular of eczema, such as atopic dermatitis, and psoriasis, and in particular of those skin diseases associated with dandruff and / or itching. hen. Furthermore, the disadvantages described above should be avoided.
  • Alums are sulfuric acid double compounds of two metals which have the composition M 1 M iri (SO 4 ) 2 .12H 2 O, where M 1 can be monovalent metal cations such as the alkali metals sodium and potassium and its organically substituted derivatives; Among others, M 111 can be the following three-fold positively charged metal cations: aluminum, gallium, indium, titanium, vanadium, chromium, manganese, iron.
  • the typical alums are those with aluminum, chrome and iron. All alums crystallize in the cubic system, usually in the octahedron form and always with 12 molecules of water of crystallization.
  • ammonium alum is an ammonium aluminum double salt containing water of crystallization. It forms water-soluble, colorless cubic crystals having a molecular weight Mr of 453.33, a density of 1.64 g / cm 3 and a melting point of 109 ° C. Kalialaun has the formula
  • Ammonium alum has been used as a deodorant crystal in the paper industry, tannery and cosmetics industry. Surprisingly, it has been found that the regular use of alum, especially ammonium alum In various skin diseases leads to a significant improvement in the appearance of the skin, with the conventional, for external use certain agents to be observed side effects do not occur, so that treatment can be carried out over a much longer period. Treatment successes were especially observed in atopic dermatitis and psoriasis.
  • the treatment is preferably carried out so that the alum according to the invention, in particular the preparation containing ammonium alum, is applied to the skin area to be treated.
  • the preparation contains alum dissolved in water, in particular ammonium alum.
  • double-distilled water is used to prevent adverse side reactions with elements contained in water, e.g. Iron, lime and the like to avoid.
  • the preparation may consist exclusively of alum dissolved in double-distilled water, in particular ammonium alum, additives of any kind not being required.
  • the aloe vera extract Chamomile flower extract may preferably be contained in the preparation in amounts of 0.5-3% by volume.
  • the chamomile flower extract acts in this case anti-inflammatory and also has desodorie ⁇ - generating and anti-bacterial effect.
  • the sea salt may preferably be present in amounts of from 0.5 to 3% by volume, in particular approximately 1.5% by volume, in the preparation.
  • sea salt from the Dead Sea is used, in particular in its natural occurrence without chemical treatment.
  • the composition of the sea salt preferably corresponds to about 50.8% magnesium chloride, 14.4% calcium chloride, 30.4% sodium chloride and 4.4% potassium chloride based on the anhydrous salts.
  • the sea salt preferably has an iodine content of> 680 ppm, in particular> 800 ppm.
  • the sea salt promotes a positive skin appearance in the context of the composition according to the invention.
  • the minerals of the sea salt from the dead sea have a healing effect on skin diseases, especially in atopic dermatitis / psoriasis.
  • the Aloe vera extract may preferably be present in the preparation in amounts of 0.5-2.5% by volume, in particular 1.5-2% by volume, particularly preferably approximately 1.7% by volume.
  • the aloe vera extract has an anti-inflammatory, soothing and irritating effect.
  • the preparation is in the form of a tincture or as a spray.
  • the ammonium alum solution contains 5-15gr of ammonium alum per 100ml of water.
  • the application is preferably carried out so that the preparation is applied 2-3 times a day on the skin to be treated. After an improvement in the appearance of the skin, the frequency of the application can be reduced.
  • a particularly preferred dosage form is achieved by wipes impregnated with the preparation according to the invention.
  • Such impregnated wipes can be easily carried by the patient in suitable packaging, wiping over the skin to be treated as needed.
  • a synthetically produced ammonium alum powder was taken or a ammonium alum natural crystal was ground to a powder. 9gr of the powder was dissolved in 100ml of double distilled water and the solution was then transferred to a vial. The solution was applied by means of a nebulizer to a dermatitis-affected area of the skin.
  • the appli ⁇ -making was carried out three times a day, ie morning after showering, afternoon and before bedtime to allow the skin in the resting phase of sleep the necessary time for a better depth effect of the preparation. In a mild to moderate skin condition of atopic dermatitis, a significant improvement in the appearance of the skin was observed after regular use for at least 14 days.
  • the procedure was analogous as described above, with the difference that not 9gr, but llgr of the powder dissolved in 100 ml of double-distilled water and the solution was then filled into a vial.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne l'alun, notamment une préparation contenant de l'alun d'ammonium pour le traitement de maladies cutanée, notamment l'eczéma, comme par exemple, la névrodermite, et le psoriasis. Cette préparation contient de l'alun, notamment de l'alun d'ammonium dissout dans de l'eau bi-distillée.
PCT/AT2013/000182 2012-11-06 2013-11-06 Alun pour le traitement de maladies cutanées WO2014071426A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE212013000223.8U DE212013000223U1 (de) 2012-11-06 2013-11-06 Alaun zur Behandlung von Hauterkrankungen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA1184/2012A AT513523A1 (de) 2012-11-06 2012-11-06 Behandlung von Hauterkrankungen
ATA1184/2012 2012-11-06

Publications (1)

Publication Number Publication Date
WO2014071426A1 true WO2014071426A1 (fr) 2014-05-15

Family

ID=49641421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT2013/000182 WO2014071426A1 (fr) 2012-11-06 2013-11-06 Alun pour le traitement de maladies cutanées

Country Status (3)

Country Link
AT (2) AT513523A1 (fr)
DE (1) DE212013000223U1 (fr)
WO (1) WO2014071426A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020091703A1 (fr) * 2018-11-01 2020-05-07 Yeditepe Universitesi Médicament pour le traitement du psoriasis et son procédé de production
RU2785038C2 (ru) * 2018-11-01 2022-12-02 Едитепе Университеси Лекарственное средство для лечения псориаза и способ его получения

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02111714A (ja) * 1988-10-20 1990-04-24 Nonogawa Shoji:Kk 化粧料
WO2001001945A1 (fr) * 1999-07-05 2001-01-11 Darren John Askew Produits a base de sels d'alun solide dans un recipient distributeur de liquides
CN101091729A (zh) * 2007-07-16 2007-12-26 陆宏成 一种治疗阴囊湿疹的熏洗药物及制备方法
WO2008140200A1 (fr) * 2007-05-10 2008-11-20 Seon-Il Kim Compositions externes pour la peau
KR20100019737A (ko) * 2008-08-11 2010-02-19 김선일 폐각의 알카리 칼슘용액을 포함하는 피부 외용제 조성물
CN101926947A (zh) * 2010-09-01 2010-12-29 黑龙江省亨发药业有限公司 治疗牛皮癣、各种顽癣、瘙痒症的中药洗药
EP2387990A1 (fr) * 2010-05-06 2011-11-23 Skinius S.R.L. Composition topique et son utilisation pour la prévention et le traitement de défauts liés à des dermopathies inflammatoires
CN102302625A (zh) * 2011-08-29 2012-01-04 邓广博 一种治疗小儿湿疹的药剂
CN102600218A (zh) * 2012-03-06 2012-07-25 孟凡友 治疗牛皮癣的外用药物及其制备方法
CN102641375A (zh) * 2012-02-13 2012-08-22 廖天源 一种治疗头癣脚癣手癣甲癣体癣股癣的药物及其制备方法

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02111714A (ja) * 1988-10-20 1990-04-24 Nonogawa Shoji:Kk 化粧料
WO2001001945A1 (fr) * 1999-07-05 2001-01-11 Darren John Askew Produits a base de sels d'alun solide dans un recipient distributeur de liquides
WO2008140200A1 (fr) * 2007-05-10 2008-11-20 Seon-Il Kim Compositions externes pour la peau
CN101091729A (zh) * 2007-07-16 2007-12-26 陆宏成 一种治疗阴囊湿疹的熏洗药物及制备方法
KR20100019737A (ko) * 2008-08-11 2010-02-19 김선일 폐각의 알카리 칼슘용액을 포함하는 피부 외용제 조성물
EP2387990A1 (fr) * 2010-05-06 2011-11-23 Skinius S.R.L. Composition topique et son utilisation pour la prévention et le traitement de défauts liés à des dermopathies inflammatoires
CN101926947A (zh) * 2010-09-01 2010-12-29 黑龙江省亨发药业有限公司 治疗牛皮癣、各种顽癣、瘙痒症的中药洗药
CN102302625A (zh) * 2011-08-29 2012-01-04 邓广博 一种治疗小儿湿疹的药剂
CN102641375A (zh) * 2012-02-13 2012-08-22 廖天源 一种治疗头癣脚癣手癣甲癣体癣股癣的药物及其制备方法
CN102600218A (zh) * 2012-03-06 2012-07-25 孟凡友 治疗牛皮癣的外用药物及其制备方法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Alum block", 28 December 2006 (2006-12-28), XP055103707, Retrieved from the Internet <URL:http://straightrazorplace.com/beginners/9251-alum-block.html> [retrieved on 20140221] *
ANONYMOUS: "Earth Clinic - print post", 1 December 2007 (2007-12-01), XP055103747, Retrieved from the Internet <URL:http://www.earthclinic.com/printpost.php?action=Feedback&id=2105&title=Apple%20Cider%20Vinegar> [retrieved on 20140221] *
ANONYMOUS: "Eczema (Atopic Dermatitis) - Health911.com - Eczema Treatment, Alternative Treatments for Eczema, Natural Remedies for Eczema, Pictures of Eczema, Eczema Photos, Eczema Cream, Eczema Causes", 19 September 2012 (2012-09-19), XP055103703, Retrieved from the Internet <URL:https://web.archive.org/web/20120919234718/http://www.health911.com/eczema> [retrieved on 20140221] *
ANONYMOUS: "Schüssler-Salze: Nr. 20. Kalium aluminium sulfuricum", 14 July 2011 (2011-07-14), XP055103495, Retrieved from the Internet <URL:https://web.archive.org/web/20110714002751/http://schuessler-salze-liste.de/ergaenzungsmittel/20-kalium-aluminium-sulfuricum.htm> [retrieved on 20140220] *
ANONYMOUS: "Stop the Itch !", 13 July 2012 (2012-07-13), XP055103711, Retrieved from the Internet <URL:https://web.archive.org/web/20120713081214/http://stoptheitch.com.au/?> [retrieved on 20140221] *
CHINESE MEDICAL JOURNAL 1979 CN, vol. 92, no. 7, 1979, pages 509 - 510, ISSN: 0366-6999 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1979, GUILIANG Y ET AL: "Alum solution for prevention of dermal maceration and erosion among rice farmers in Shanghai districts", XP002721060, Database accession no. EMB-1979253731 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020091703A1 (fr) * 2018-11-01 2020-05-07 Yeditepe Universitesi Médicament pour le traitement du psoriasis et son procédé de production
CN113056281A (zh) * 2018-11-01 2021-06-29 耶迪特普大学 用于治疗牛皮癣的药物及其生产方法
US20210393724A1 (en) * 2018-11-01 2021-12-23 Yeditepe Universitesi Medicine for treatment of psoriasis and production method thereof
JP2022505933A (ja) * 2018-11-01 2022-01-14 イェディテペ・ウニヴェルシテシ 乾癬の治療のための医薬及びその製造方法
RU2785038C2 (ru) * 2018-11-01 2022-12-02 Едитепе Университеси Лекарственное средство для лечения псориаза и способ его получения
CN113056281B (zh) * 2018-11-01 2023-05-26 耶迪特普大学 用于治疗牛皮癣的药物及其生产方法
JP7377562B2 (ja) 2018-11-01 2023-11-10 イェディテペ・ウニヴェルシテシ 乾癬の治療のための医薬及びその製造方法

Also Published As

Publication number Publication date
AT15197U1 (de) 2017-02-15
DE212013000223U1 (de) 2015-06-10
AT513523A1 (de) 2014-05-15

Similar Documents

Publication Publication Date Title
EP2214658B1 (fr) Préparation contenant des osmolytes destinée à être employée en cas de muqueuses sèches
WO2010018418A1 (fr) Formulation à base de clinoptilolite micronisée utilisée en tant qu’agent thérapeutique produisant un silicium extrêmement biodisponible
DE2818553A1 (de) Zusammensetzung zur behandlung von proliferativen hautkrankheiten
DE3879811T2 (de) Pharmazeutische Zusammensetzung und ihre Verwendung.
DE68912195T2 (de) Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis.
DE60018569T2 (de) Neue Verwendung von hyposmotischen Salzlösungen und darauf basierendes Medikament
DE102008036725B4 (de) Pharmazeutische Zusammensetzung für die nasale Applikation
DE1617320B2 (de) Hautbehandlungsmittel
DE69804597T2 (de) Salbe zur behandlung von verbrennungen und anderen hautkrankheiten
WO2014071426A1 (fr) Alun pour le traitement de maladies cutanées
DE3832401C2 (fr)
WO2006108414A2 (fr) Agent pour assurer la therapie et la prophylaxie de maladies de la peau
DE102006044447B4 (de) Gelartiges Basenpräparat auf Basis ätherischer Ölmischungen zur dermalen und transdermalen Anwendung
CH676424A5 (fr)
WO2008046606A2 (fr) Composition topique pour le traitement d&#39;eczéma
EP1955591A1 (fr) Produit de soin et traitement antimicrobien de la peau
DE4339750A1 (de) Mittel zur Behandlung von Akne, seborrhoischem Ekzem und anderen Hautkrankheiten
DE10143146B4 (de) Antiarthrotische Zubereitung und deren Verwendung
DE102009052808A1 (de) Eine Heilsalbe mit mindestens einem homöopathisch verdünnten Mineralsalz
DE10161729A1 (de) Medizinische bzw. pharmazeutische Salbenzubereitung
DE202009013734U1 (de) Mineralpulvermischung
CH677878A5 (fr)
DE19821971A1 (de) Arzneimittel zur Behandlung von Psoriasis oder Neurodermitis
DE10238161A1 (de) Mineralstoff-Ampulle für die mucosale und topische Wirkstoffapplikation
DE102006061186A1 (de) Verwendung von Aluminium- und Chlor-haltigen Verbindungen zur äußerlichen Anwendung bei allergischen Hautreaktionen, Entzündungen, Juckreiz und/oder Schwellungen der Haut

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13795406

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2120130002238

Country of ref document: DE

Ref document number: 212013000223

Country of ref document: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13795406

Country of ref document: EP

Kind code of ref document: A1